AbbVie has formed a collaboration with Principia Biopharma, a private, clinical-stage biopharmaceutical company, for the development of oral immunoproteasome inhibitors in the field of immunology.

The collaboration focuses on the creation and development of orally bioavailable, selective inhibitors of the immunoproteasome subunits to target autoimmunity. AbbVie and Principia will collaborate on research and preclinical studies. Upon successful completion, AbbVie will be responsible for ongoing clinical development and commercialization of viable compounds resulting from the partnership. Financial terms were not disclosed.

Source: AbbVie